WordNet
- an antineoplastic drug often used to treat brain tumors or Hodgkins disease
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 再発高グレード神経膠腫のマネージメント management of recurrent high grade gliomas
- 2. 未分化乏突起膠腫のマネージメント management of anaplastic oligodendroglial tumors
- 3. ニトロソウレア誘発性肺障害 nitrosourea induced pulmonary injury
- 4. 低悪性度神経膠腫のマネージメント management of low grade glioma
- 5. 転移性黒色腫（メラノーマ）の細胞傷害性化学療法 cytotoxic chemotherapy for metastatic melanoma
English Journal
- Nitrosoureas in the Management of Malignant Gliomas.
- Brandes AA1, Bartolotti M2, Tosoni A2, Franceschi E2.
- Current neurology and neuroscience reports.Curr Neurol Neurosci Rep.2016 Feb;16(2):13. doi: 10.1007/s11910-015-0611-8.
- Nitrosoureas represent one of the most active classes of agents in the treatment of high-grade gliomas and glioblastoma. In clinical practice, the most commonly used compounds are lomustine (either alone or in combination with procarbazine and vincristine), carmustine, and fotemustine. Given their t
- PMID 26750128
- Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
- Heiland DH1, Masalha W1, Franco P1, Machein MR1, Weyerbrock A2.
- Journal of neuro-oncology.J Neurooncol.2016 Feb;126(3):567-75. doi: 10.1007/s11060-015-2002-z. Epub 2015 Nov 27.
- Bevacizumab (BEV) is widely used for treatment of patients with recurrent glioblastoma multiforme (GBM). 1-(2-Chlorethyl)-cyclohexyl-nitrosourea (CCNU, lomustine) monotherapy is an approved chemotherapeutical option for recurrent GBM. Recent evidence demonstrated a survival benefit of combined treat
- PMID 26614518
- LACE versus BEAM conditioning in relapsed and refractory lymphoma transplant: retrospective multicenter analysis of toxicity and efficacy.
- Khattry N1, Gupta A2, Jain R3, Gore A4, Thippeswamy R2, Jeevangi N2, Kannan S5, Nair R2, Saikia T4.
- International journal of hematology.Int J Hematol.2016 Jan 4. [Epub ahead of print]
- We compared the lomustine, cytarabine, cyclophosphamide and etoposide (LACE) and BCNU, etoposide, cytarabine, melphalan (BEAM) conditioning regimens for toxicity, engraftment kinetics, and efficacy in 139 patients undergoing autologous hematopoietic stem cell transplant for primary refractory or rel
- PMID 26729297
Related Pictures
★リンクテーブル★
| リンク元 | 「ロムスチン」 |